Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically driven, global, full-service clinical contract research organization (CRO) that regularly issues detailed financial and operational updates. This news page aggregates Medpace news, including quarterly and annual earnings releases, conference call announcements, and other disclosures that matter to investors following MEDP stock and the clinical research sector.
Medpace’s press releases focus on revenue trends, GAAP net income, EBITDA and EBITDA margin, backlog levels, and net new business awards, along with net book-to-bill ratios. The company also provides financial guidance ranges for upcoming periods, discussing expected revenue, net income, and EBITDA, as well as assumptions related to tax rates, interest income, and diluted share counts. These updates help readers understand how demand for Medpace’s Phase I–IV clinical development services is evolving over time.
In addition to earnings results, Medpace frequently announces the dates and times of upcoming earnings releases and conference calls, along with webcast access details and references to supplemental slide presentations in its investors section. The company’s news also touches on capital allocation decisions, such as stock repurchase program authorizations and remaining repurchase capacity, and occasionally on financing arrangements, as reflected in filings related to its unsecured credit facility.
Because Medpace operates as a global CRO serving biotechnology, pharmaceutical and medical device sponsors, its news flow offers insight into the broader outsourcing environment for clinical research and development. Investors, analysts, and industry observers can use this page to review historical announcements, monitor new earnings releases, and track changes in guidance, backlog, and booking trends over time.
Medpace Holdings, Inc. (MEDP) reported a revenue of $351.2 million for Q2 2022, a 26.2% increase from $278.3 million a year earlier. Net new business awards rose by 16.3% to $450.6 million, achieving a net book-to-bill ratio of 1.28x. The company posted a GAAP net income of $49.4 million, or $1.46 per diluted share, marking a significant increase from the $39.9 million in Q2 2021. EBITDA climbed 42.0% to $68.1 million, equating to a margin of 19.4%. Medpace forecasts 2022 revenue between $1.405 billion and $1.435 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its Q2 2022 financial results on July 25, 2022, after market close. A conference call is scheduled for July 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can register via a provided link or join through the investors section of the Medpace website. A supplemental slide presentation will also be made available ahead of the call. Medpace is a full-service clinical contract research organization focusing on biotechnology, pharmaceuticals, and medical devices.
Medpace Holdings reported a 27.3% increase in revenue for Q1 2022, reaching $330.9 million, up from $260.0 million in Q1 2021. The company achieved net new business awards of $423.0 million, resulting in a net book-to-bill ratio of 1.28x. GAAP net income rose to $61.3 million ($1.69 per diluted share), compared to $43.3 million ($1.14 per diluted share) last year. EBITDA increased by 31.3% to $70.4 million, with a margin of 21.3%. The firm forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace (MEDP), a clinical research organization, has partnered with Matthew 25: Ministries to support humanitarian efforts in Ukraine. The organization donated over $2.5 million for the shipping and distribution of essential aid to hundreds of thousands in need. Both Medpace and Matthew 25 emphasize the urgency of the crisis and the significant impact of this contribution. Medpace operates in Ukraine and Poland, making this initiative particularly relevant for its employees and community.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its first quarter 2022 financial results on April 25, 2022, after market close. A conference call is scheduled for April 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can join by dialing 800-219-7113 (domestic) or 574-990-1030 (international) with passcode 3191816, or access the call via webcast on Medpace’s website. The call will be available for replay until May 3, 2022.
Medpace Holdings, Inc. (MEDP) reported a revenue increase of 18.8% to $308.6 million for Q4 2021, compared to $259.7 million in Q4 2020. For the full year 2021, revenue rose 23.4% to $1,142.4 million. The company secured $458.7 million in net new business awards for Q4 2021, up 27.9%, leading to a book-to-bill ratio of 1.49x. However, Q4 GAAP net income decreased slightly to $50.0 million from $50.9 million in the previous year. Full-year net income was $181.8 million. Medpace forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its fourth quarter and fiscal year 2021 financial results after market close on February 14, 2022. A conference call is scheduled for February 15, 2022, at 9:00 a.m. ET to discuss the results. Interested parties can participate by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 9164466. The call will be accessible via webcast on the company's website, with a replay available until February 22, 2022.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 28.3% increase in revenue for Q3 2021, reaching $295.6 million, compared to $230.4 million in Q3 2020. Net new business awards also rose by 29.4% to $408.0 million, leading to a net book-to-bill ratio of 1.38x. GAAP net income was $48.6 million, or $1.29 per diluted share, reflecting a net income margin of 16.4%. The company forecasts 2021 revenue of $1.135 billion to $1.145 billion and 2022 revenue of $1.400 billion to $1.460 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) announced it will report its third quarter 2021 financial results after market close on October 25, 2021. A conference call to discuss these results is scheduled for October 26, 2021, at 9:00 a.m. ET. Participants can join by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 5177474. The call will also be accessible via webcast on Medpace's investor website, with a replay available until November 2, 2021.
Medpace Holdings (Nasdaq: MEDP) will present at Baird’s Global Healthcare Conference on September 14, 2021, at 8:30 a.m. ET. The presentation will feature Jesse Geiger, President, and Kevin Brady, CFO. A live webcast will be available on the company’s website with replay options following the event.
Medpace is a global clinical contract research organization providing comprehensive clinical development services across various therapeutic areas, employing around 4,100 people in 40 countries.